<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7360901\results\search\testTrace\results.xml">
  <result pre="aÂ global case-fatality rate of ~6%. Due to the limited" exact="testing" post="capacity in many countries, especially at the beginning of"/>
  <result pre="as well as differences in health status, health care, COVID-19" exact="treatment" post="and cause of death assessment (i.e. did aÂ person"/>
  <result pre="transmission rate of 44%, implying that containment measures based on" exact="isolation" post="of virus shedders will only be effective if contact"/>
  <result pre="on isolation of virus shedders will only be effective if" exact="contact tracing" post="includes the 2â€&quot;3Â days before symptom onset in the"/>
  <result pre="isolation of virus shedders will only be effective if contact" exact="tracing" post="includes the 2â€&quot;3Â days before symptom onset in the"/>
  <result pre="several studies, SARS-CoVâ€‘2 RNA has been demonstrated by reverse transcription-quantitative" exact="polymerase chain reaction" post="(RT-qPCR) analysis (see below) in stool and sewage, and"/>
  <result pre="organoids [26], and the viral NÂ has been detected by" exact="immunofluorescence" post="microscopy in the cytoplasm of gastric, duodenal and rectal"/>
  <result pre="and minks have been shown to be permissive to SARS-CoVâ€‘2" exact="infection" post="(see, for example, [28]) and evidence has been obtained"/>
  <result pre="case-fatality rate of 2.3% [30]. In mildly affected individuals the" exact="infection" post="remains largely restricted to the upper respiratory tract, while"/>
  <result pre="In 6Â of these patients, radiographic abnormalities were observed before" exact="testing" post="positive for SARS-CoVâ€‘2 RNA. Consolidation and ground-glass opacities were"/>
  <result pre="neuroendocrine imbalance and other pathophysiological changes induced by the airway" exact="infection" post="[43]. For information on the clinical management of (severe)"/>
  <result pre="the Electronic Supplementary Material. In the large majority of persons," exact="infection" post="with SARS-CoVâ€‘2 is rapidly and efficiently controlled by the"/>
  <result pre="thought to play an important role in limiting the viral" exact="infection" post="(to the upper respiratory tract). Based on previous research"/>
  <result pre="natural killer (NK) cells and lymphocytes to the site(s) of" exact="infection" post="and participate in the activation of these immune cells."/>
  <result pre="In the case of an adequate immune response, the virus" exact="infection" post="is subsequently cleared by the concerted action of innate"/>
  <result pre="measure adaptive immunity (i.e. antibodies and TÂ lymphocytes) against SARS-CoVâ€‘2" exact="infection" post="[56, 57]. Although not specific, radiography to visualise lung"/>
  <result pre="to quantify functional virus particles can also aid in the" exact="diagnosis" post="of COVID-19. Virological tests RT-qPCR-based laboratory assays on upper"/>
  <result pre="presently the standard tests to detect ongoing SARS-CoVâ€‘2 infections. RNA-virus" exact="detection" post="by RT-qPCR is aÂ multistep procedure involving the extraction"/>
  <result pre="thermostable DNA polymerase and virus-specific DNA primers and the real-time" exact="detection" post="of the amplification products using fluorescence-based methods (see, for"/>
  <result pre="https://www.youtube.com/watch?v=ThG_02miq-4 for an illustrative movie). The preferred specimens for the" exact="detection" post="of SARS-CoVâ€‘2 RNA by RT-qPCR are nasopharyngeal samples collected"/>
  <result pre="samples, SARS-CoVâ€‘2 RNA is also frequently detected in faeces (reflecting" exact="infection" post="of the gastrointestinal tract), occasionally in blood samples (indicative"/>
  <result pre="recognising another epitope of the same virion protein (the so-called" exact="detection" post="antibody) is applied to the well, followed by an"/>
  <result pre="well, followed by an enzyme-conjugated third antibody directed against the" exact="detection" post="antibody. AÂ colourless substrate is then added to the"/>
  <result pre="led to the development of immunochromatography strips for fast instrument-free" exact="testing" post="employing capillary movement (Fig.Â 3b). These strips contain aÂ"/>
  <result pre="antigen in the clinical specimen. Fig. 3 a,Â bÂ Antigen" exact="detection" post="methods. aÂ Sandwich ELISA. bÂ Immunochromatography test In general,"/>
  <result pre="methods. aÂ Sandwich ELISA. bÂ Immunochromatography test In general, antigen" exact="detection" post="assays are less sensitive than genome detection methods, resulting"/>
  <result pre="In general, antigen detection assays are less sensitive than genome" exact="detection" post="methods, resulting in aÂ higher rate of false-negative results."/>
  <result pre="aÂ person is infected with SARS-CoVâ€‘2. The formats of antibody" exact="detection" post="tests are similar to those of the antigen detection"/>
  <result pre="antibody detection tests are similar to those of the antigen" exact="detection" post="assays except that viral proteins (most SÂ or N,"/>
  <result pre="also be used for assessment of immunity resulting from natural" exact="infection" post="or active immunisation. However, it is not yet clear"/>
  <result pre="prevention In theory, SARS-CoVâ€‘2 could be completely eradicated by strict" exact="isolation" post="of all infectious sources similar to the extinction of"/>
  <result pre="effective SARS-CoVâ€‘2 vaccine (see https://docs.google.com/spreadsheets/d/16DbPhF9OD0MHHtCR12of6yUcfiRzP_-XGkynEbnipds/edit#gid=1804775590 for an overview) to block" exact="infection" post="or, at least, mitigate the consequences of infection. Although"/>
  <result pre="vaccines. This will, however, not obviate the need for extensive" exact="testing" post="of candidate vaccines in appropriate animal models and clinical"/>
  <result pre="non-replicating vaccines include (1)Â wild-type SARS-CoVâ€‘2 particles inactivated by chemical" exact="treatment" post="or high-energy radiation, (2)Â non-replicating viral vectors directing the"/>
  <result pre="complement receptors present at their surface. This antibody-dependent enhancement of" exact="infection" post="has previously been observed for feline infectious peritonitis virus"/>
  <result pre="vaccination, another strategy consists of thwarting the virus once an" exact="infection" post="has revealed itself by the administration of antiviral drugs"/>
  <result pre="severe disease [69]. SARS-CoVâ€‘2 replication can also be inhibited by" exact="treatment" post="with nucleoside analogues (usually administered as prodrug) that interfere"/>
  <result pre="the subgenomic mRNAs. Nucleoside analogues under current investigation for the" exact="treatment" post="of COVID-19 include ribavirin, favipiravir (T-705) and remdesivir (GS-5734)."/>
  <result pre="to the viral genome and promote its degradation. By simultaneous" exact="treatment" post="of COVID-19 with multiple siRNAs targeting different parts of"/>
  <result pre="63, 71]. There may, however, also be aÂ downside to" exact="treatment" post="of COVID-19 with interferons given the recent finding that"/>
  <result pre="general, in patients at risk of developing severe disease following" exact="infection" post="with SARS-CoVâ€‘2, antiviral drug therapy should be started as"/>
  <result pre="Antiviral drugs may also be employed as prophylactics to prevent" exact="infection" post="or to reduce virus shedding and thereby the risk"/>
  <result pre="found at https://docs.google.com/spreadsheets/d/16DbPhF9OD0MHHtCR12of6yUcfiRzP_-XGkynEbnipds/edit#gid=1206197573. When using antivirals or immunomodulators in the" exact="treatment" post="of COVID-19, one should be vigilant for drug-induced organ"/>
  <result pre="studies have identified venous and arterial thrombosis secondary to SARS-CoVâ€‘2" exact="infection" post="as aÂ major complication of COVID-19, which likely contributes"/>
  <result pre="cases, (2)Â disturbance of the angiotensin-2/angiotensin-(1â€&quot;7)Â balance and (3)Â SARS-CoVâ€‘2" exact="infection" post="of endothelial cells [81]. More extensive discussions about the"/>
  <result pre="serious threat to human health. The outcome of aÂ SARS-CoVâ€‘2" exact="infection" post="is highly variable and dependent on multiple factors, including"/>
  <result pre="proteins of SARS-CoV and other coronavirusesAntiviral Res20141099710924995382 18.RussellTWHellewellJJarvisCIet al.Estimating the" exact="infection" post="and case fatality ratio for coronavirus disease (COVID-19) using"/>
  <result pre="al.SARS-CoV-2 productively infects human gut enterocytesScience202010.1126/science.abc166932631886 27.XiaoFTangMZhengXet al.Evidence for gastrointestinal" exact="infection" post="of SARS-CoV-2Gastroenterology20201581831183332142773 28.ShiJWenZZhongGet al.Susceptibility of ferrets, cats, dogs, and"/>
  <result pre="humoral and cellular immunity in COVID-19 convalescent individualsImmunity20205297197732413330 56.ChengMPPapenburgJDesjardinsMet al.Diagnostic" exact="testing" post="for severe acute respiratory syndrome-related coronavirus 2: aÂ narrative"/>
  <result pre="al.The possible mechanisms of action of 4-aminoquinolines (chloroquine/hydroxychloroquine) against SARS-CoV-2" exact="infection" post="(COVID-19): aÂ role for iron homeostasis?Pharmacol Res202015810490432430286 69.BlochEMShohamSCasadevallAet al.Deployment"/>
  <result pre="Res202015810490432430286 69.BlochEMShohamSCasadevallAet al.Deployment of convalescent plasma for the prevention and" exact="treatment" post="of COVID-19J Clin Invest20201302757276532254064 70.LeeAJAshkarAAThe dual nature of type"/>
  <result pre="ARBs, ACEIs and statins on clinical outcomes of 1 COVID-19" exact="infection" post="among nursing home residents2020 77.KlokFAKruipMJHAvan der MeerNJMet al.Confirmation of"/>
  <result pre="so far?Acta Haematol202010.1159/00050823332396903 81.TeuwenLAGeldhofVPasutACarmelietPCOVID-19: the vasculatureNat Rev Immunol20202038939132439870 82.TangNBaiHChenXet al.Anticoagulant" exact="treatment" post="is associated with decreased mortality in severe coronavirus disease"/>
  <result pre="and the cardiovascular system: implications for risk assessment, diagnosis, and" exact="treatment" post="optionsCardiovasc Res202010.1093/cvr/cvaa10632582932 92.DhakalBPSweitzerNKIndikJHAcharyaDWilliamPSARS-CoV-2 infection and cardiovascular disease: COVID-19 heartHeart"/>
  <result pre="implications for risk assessment, diagnosis, and treatment optionsCardiovasc Res202010.1093/cvr/cvaa10632582932 92.DhakalBPSweitzerNKIndikJHAcharyaDWilliamPSARS-CoV-2" exact="infection" post="and cardiovascular disease: COVID-19 heartHeart Lung Circ202010.1016/j.hlc.2020.05.10132601020 93.GanatraSDaniSSShahSet al.Management"/>
 </snippets>
</snippetsTree>
